Rapid and Sensitive Quantification of Osimertinib in Human Plasma Using a Fully Validated MALDI–IM–MS/MS Assay
Open Access
- 13 July 2020
- Vol. 12 (7), 1897
- https://doi.org/10.3390/cancers12071897
Abstract
The third-generation tyrosine kinase inhibitor (TKI), osimertinib, has revolutionized the treatment of patients with non-small cell lung carcinoma with epidermal growth factor receptor (EGFR)-activating mutation, and resistant to first- and second-generation TKIs. Osimertinib is now also proposed as a first-line therapy, thus extending the scope of applications in lung oncology. Personalized medicine approaches are still necessary to monitor if patients are exposed to adequate concentrations of osimertinib during their treatment. It would also help to understand the appearance of new resistances in patients after several months of dosing with osimertinib. Liquid chromatography–tandem mass spectrometry (LC–MS/MS) is currently the gold standard for the quantification of drugs in plasma enabling pharmacokinetic analyses and patient monitoring. In the present study, we propose an alternative to LC–MS/MS methods for the rapid and sensitive quantification of osimertinib in plasma using matrix-assisted laser desorption/ionization (MALDI) –MS. The presented assay requires only 3 min per sample for their preparation, analysis, and data extraction, and less than 3 h for quantification. A lower limit of quantification (LLOQ) of 5 ng/mL in plasma was retrieved. The method was fully validated, following the guidelines of the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for bioanalytical method validation. The present developments prove the importance to consider alternative MS assays for time-efficient quantification of small molecule inhibitors in plasma in the context of personalized medicine for targeted therapies.Keywords
Funding Information
- Dietmar Hopp Stiftung (PROMISE)
- Deutsche Forschungsgemeinschaft (UNITE)
This publication has 21 references indexed in Scilit:
- Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patientsJournal of Pharmaceutical and Biomedical Analysis, 2018
- Rapid Quantification of 25-Hydroxyvitamin D3 in Human Serum by Matrix-Assisted Laser Desorption/Ionization Mass SpectrometryJournal of the American Society for Mass Spectrometry, 2018
- Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometryActa Neuropathologica Communications, 2018
- Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Population pharmacokinetics and exposure‐response of osimertinib in patients with non‐small cell lung cancerBritish Journal of Clinical Pharmacology, 2017
- Bio-analytical method based on MALDI-MS analysis for the quantification of CIGB-300 anti-tumor peptide in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2015
- Ultrafast Selective Quantification of Methotrexate in Human Plasma by High-Throughput MALDI-Isotope Dilution Mass SpectrometryBioanalysis, 2011
- Correction: Ultra-Fast Analysis of Plasma and Intracellular Levels of HIV Protease Inhibitors in Children: A Clinical Application of MALDI Mass SpectrometryPLOS ONE, 2010
- Ultra-Fast Analysis of Plasma and Intracellular Levels of HIV Protease Inhibitors in Children: A Clinical Application of MALDI Mass SpectrometryPLOS ONE, 2010
- Quantification of bile acids directly from plasma by MALDI-TOF-MSAnalytical and Bioanalytical Chemistry, 2004